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Rashmi Lakshminarayana1, Duolao Wang2, David Burn3, K. Ray Chaudhuri4, Clare Galtrey5, Natalie Valle Guzman6, Bruce Hellman1,
Ben James1, Suvankar Pal7, Jon Stamford8, Malcolm Steiger9, R. W. Stott6, James Teo10, Roger A. Barker11, Emma Wang12,
Bastiaan R. Bloem13, Martijn van der Eijk13, Lynn Rochester3 and Adrian Williams14
The progressive nature of Parkinson’s disease, its complex treatment regimens and the high rates of comorbid conditions make
self-management and treatment adherence a challenge. Clinicians have limited face-to-face consultation time with Parkinson’s
disease patients, making it difﬁcult to comprehensively address non-adherence. Here we share the results from a multi-centre
(seven centres) randomised controlled trial conducted in England and Scotland to assess the impact of using a smartphone-based
Parkinson’s tracker app to promote patient self-management, enhance treatment adherence and quality of clinical consultation.
Eligible Parkinson’s disease patients were randomised using a 1:1 ratio according to a computer-generated random sequence,
stratiﬁed by centre and using blocks of variable size, to intervention Parkinson’s Tracker App or control (Treatment as Usual).
Primary outcome was the self-reported score of adherence to treatment (Morisky medication adherence scale −8) at 16 weeks.
Secondary outcomes were Quality of Life (Parkinson’s disease questionnaire −39), quality of consultation for Parkinson’s disease
patients (Patient-centred questionnaire for Parkinson’s disease), impact on non-motor symptoms (Non-motor symptoms
questionnaire), depression and anxiety (Hospital anxiety and depression scale) and beliefs about medication (Beliefs about
Medication Questionnaire) at 16 weeks. Primary and secondary endpoints were analysed using a generalised linear model with
treatment as the ﬁxed effect and baseline measurement as the covariate. 158 patients completed the study (Parkinson’s tracker
app = 68 and TAU = 90). At 16 weeks Parkinson’s tracker app signiﬁcantly improved adherence, compared to treatment as usual
(mean difference: 0.39, 95%CI 0.04–0.74; p = 0.0304) with no confounding effects of gender, number of comorbidities and age.
Among secondary outcomes, Parkinson’s tracker app signiﬁcantly improved patients’ perception of quality of consultation (0.15,
95% CI 0.03 to 0.27; p = 0.0110). The change in non-motor symptoms was −0.82 (95% CI −1.75 to 0.10; p = 0.0822). 72% of
participants in the Parkinson’s tracker app group continued to use and engage with the application throughout the 16-week trial
period. The Parkinson’s tracker app can be an effective and novel way of enhancing self-reported medication adherence and quality
of clinical consultation by supporting self-management in Parkinson’s disease in patients owning smartphones. Further work is
recommended to determine whether the beneﬁts of the intervention are maintained beyond the 16 week study period.
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INTRODUCTION
Parkinson’s disease (PD) is the second most common neurodegen-
erative disorder, after Alzheimer’s disease1 and affects 6.3 million
people worldwide.2 It is a disabling condition and has a signiﬁcant
impact on patient’s Quality of Life (QoL).3 Non-motor symptoms
such as depression, anxiety, fatigue and sleep disturbance are
frequently overlooked by clinicians4 and contribute to signiﬁcant
burden on people with PD and their carers.5 Comorbidity is
common in PD. Dementia, arthritis, ischaemic heart disease, diabetes
and falls are amongst the commonly associated co-morbidities.6
Managing motor and non-motor symptoms and the risk of side
effects from medications leads to complex treatment regimes.7
The number of drugs and the frequency with which they are taken
typically increases as the diseases progresses.8,9 The addition of
medications to manage associated co-morbidities further adds to
the complexity of managing dosing schedules.
Patient centred care—“providing care that is respectful of and
responsive to individual patient preferences, needs and values,
and ensuring that patient values guide all clinical decisions”10—is
a core aspect of quality of care and increases treatment adherence
among chronically ill patients and job satisfaction among health
professionals.11 Self-management support and shared decision-
making have been identiﬁed as two promising ways to support
and empower PD patients.11
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Self-management support refers to increasing patient participa-
tion, collaborative goal setting, treatment planning and assisting
patients to gain control over their lives.12 It can teach PD patients
how to better utilise healthcare resources and how to form more
effective partnerships with their care providers.11
The reported prevalence of non-adherence to prescribed therapy
in PD varies from 0 to 60–70%.1 Medication nonadherence can be
unintentional or intentional.13 Unintentional nonadherence involves
intending to take a medication as instructed but failing to do so for
some reason (e.g. forgetfulness, carelessness) and is inﬂuenced by
patient characteristics, treatment factors, and patient–provider
issues.14 Intentional nonadherence involves making a reasoned
decision not to take a medication as instructed based on
perceptions, feelings or beliefs. It reﬂects a rational decision-
making process by the patient whereby the beneﬁts of treatment
are weighed against any adverse effects of the treatment.14 The
direct and indirect costs of nonadherence in the USA is between
$100–$300 billion/year15 and over £930 million/year in England.16
Nonadherence is linked to poor QoL, increased hospitalisation
admissions and premature mortality.17,18
Delivering self-management support digitally, including support
for understanding and managing treatment has shown improve-
ments health outcomes and processes of care in other chronic
conditions.19 The SMART-PD trial aimed to assess outcomes of a
patient centred smartphone and Internet assisted self-
management and treatment adherence tool, the Parkinson’s
Tracker App (PTA), to manage PD. Two versions of the PTA were
assessed in a previous randomised pilot study in collaboration
with the Cure Parkinson’s Trust UK.20 Patient feedback on design,
features and usability from this study was used to update the PTA
for the current trial.
Our primary objective was to assess if patients with PD who use
a PTA for 16 weeks in addition to TAU (treatment as usual) show
improved self-reported medication adherence. Our secondary
objectives were to investigate whether patients who receive the
PTA and those who receive TAU differ in terms of QoL, quality of
clinical consultation and symptom control.
RESULTS
We invited 737 patients to participate. Of the 522 (70.8%) who
responded, 277 (53%) did not meet the inclusion criteria, 65 (12.4%)
declined to participate and 180 (34.5%) could not take part due to
other reasons including not having devices with iPhone/iPad or
Android operating systems or being unable to make it to the Out-
Patient appointment. Figure 1 highlights the trial CONSORT ﬂow.
Assessed for eligibility 
(n=737)
Excluded  (n= 522) 
- Not meeting inclusion criteria (n=277) 
- Declined to participate (n=65) 
- Other reasons (n=180) 
(Devices other than iOS or Android, could not 
come to OP appointment) 
Excluded from analysis (n= 18) 
Did not fill in questionnaires (n=18) 
Analysed  (n= 68) 
Lost to follow-up (n=10) 
- No response to phone call 2 and /or visit 2 
request  
Discontinued intervention (n= 8) 
- Technical issues = 3  
- Not useful at the moment = 5 
Allocated to PTA  (n=106) 
• Received allocated intervention (n= 104)
• Did not receive allocated intervention (n= 2)  
- Did not sign informed consent = 1 
- Incorrect randomisation  = 1 
Lost to follow-up (n= 4) 
- No response to phone call 2 and /or visit 2 
request  
Discontinued trial (n=4) 
- Not interested anymore = 3 
- Withdrew after visit 1 = 1 
Allocated to TAU (n=109) 
• Received allocated intervention (n= 108)
• Did not receive allocated intervention (n= 1)
- Incorrect randomisation  = 1 
 Excluded from analysis (n=10)                         
Did not fill in questionnaires (n=10)
Analysed  (n= 90)
Randomised (n= 215) 
Fig. 1 Trial CONSORT patient ﬂow diagram
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The remaining 215 patients were randomly assigned to PTA
(n = 106) and control (n = 109). Of these, 10 patients (9.4%) and 4
(3.7%) were lost to follow-up in PTA and TAU arm, respectively. Of
those who completed the trial, we analysed data from 68 (79%)
and 90 (90%) in the PTA and TAU arms, respectively. We closed
recruitment due to funding restrictions.
Baseline data were comparable between the two groups
(Table 1). Participants took medications for 42 co-morbid
conditions in addition to PD (Table 2). Participants took between
1 to 5 types of medications to manage PD. The majority of
participants were White (n = 206) with a small number being
Asian/Asian British (n = 6) and Black/Black British (n = 2).
Primary outcome
Participants in the PTA group (n = 68) showed an improvement in
MMAS-8 score of 0.39 points over TAU group in Intent-to-Treat
analysis (Table 3) (95% CI 0.04 to 0.74; p = 0.0304), translating to
better self-reported adherence to medication. These ﬁndings were
replicated in Per Protocol population (0.41, 95% CI 0.06 to 0.76;
p = 0.0227). This translated into a 6.6% reduction in low adherence
category in the PTA group compared to 1.4% reduction in the TAU
group (Fig. 2).
When the ANCOVA analysis was adjusted for the covariates
gender, number of comorbidities and age, the effect of treatment
remained statistically signiﬁcant (0.38, 95%CI 0.03 to 0.73;
p = 0.0301 (Table 3), illustrating that the result of improvement
is robust even after controlling for the three covariates on the
analysis.
Subgroup analyses with interaction testing were performed to
determine whether the improvement in the primary end point
was consistent across four important subgroups (Table 4). No
signiﬁcant interactions were observed. However, results revealed
that those older than 61, females and those with greater than one
comorbidity tended to beneﬁt more from PTA than their
counterparts.
Secondary outcomes
Among the secondary outcomes (Table 5) the PCQ-PD improved in
the PTA group (p = 0.0110). Quality of PD care was assessed in 6
dimensions in PCQ-PD (i.e. information, collaboration, accessibility,
empathy, patient involvement and emotional support). Statistically
signiﬁcant improvements were seen in patient perception of
collaboration and patient involvement in decision-making subscales.
The difference between the PTA and TAU groups for the
secondary endpoint of Non-Motor Symptom Questionnaire
was −0.82 (p = 0.0822) and for the QoL questionnaire (PDQ-39)
was −0.22 (p = 0.9102). Results for individual subdomains of PDQ-
39 are presented in Supplementary Table 1.
There were no statistically signiﬁcant differences between the
groups with regards to other secondary outcomes. These ﬁndings
were consistent with per protocol analysis.
Analysis of PTA use
Seventy-two per cent of participants in the PTA group continued
to use and engage with the application throughout the 112-day
trial period (Table 6). They used the app almost every other day on
average, with some people using the app every day (Table 7).
We undertook further analysis of PTA usage in the PTA group in
March 2016, after the end of the study in June 2015. The table
below (Table 8) highlights that 29% of participants continued to
use the app for over 6 months after the trial had ended.
DISCUSSION
Compared to TAU, participants using the PTA for 16 weeks
reported statistically signiﬁcant improvements in short-term self-
reported medication adherence and subjective quality of clinical
consultation. These ﬁndings suggest that the PTA can be useful in
improving outcomes and processes of care in people with PD,
similar to results seen in other chronic conditions such as diabetes
and asthma.19 Given that typical clinical follow-up of patients with
PD by clinical care teams in the UK occurs approximately every
6 months (by consultants or nurse specialists), this ﬁnding
suggests PTA is useful in improving care for a signiﬁcant period
of time between clinic consultations.7
In early stages of the disease, patients usually take a single
drug21 and over half of patients take two to three drugs three to
four times daily in later stages.9,22 This partly explains why the
effect of the PTA in subgroups was signiﬁcant amongst those
older than the median age. The complexity of treatment along
with PD affecting cognitive processes such as sorting or planning
tasks23 might explain why the PTA helped in improving adherence
as medication reminders and symptom tracking were core
features.
Factors affecting medication non-adherence in PD patients
include clinical (i.e. mood disorders, cognitive impairment, poor
Table 1. Baseline demographics of participants
Variable PTA (n= 94) mean (SD) TAU (n= 107) mean (SD) All (n= 201)
Age at screening (year) 59.86 (9.13) 60.71 (10.26) 60.31 (9.73)
Gender Female 34 (36.2%) 45 (42.1%) 79 (39.3%)
Male 60 (63.8%) 62 (57.9%) 122 (60.7%)
Number of comorbidities 1.39 (1.66) 1.32 (1.59) 1.35 (1.62)
Parkinson’s disease duration (years) 5.47 (4.18) 5.47 (4.89) 5.47 (4.56)
Morisky medication adherence scale (MMAS-8) 6.03 (1.57) 5.82 (1.48) 5.92 (1.52)
QoL (PDQ-39) 154.53 (27.98) 151.43 (27.70) 152.88 (27.81)
Patient-centred questionnaire for Parkinson’s disease (PCQ-PD) 1.91 (0.53) 1.93 (0.51) 1.92 (0.52)
Non-motor symptoms questionnaire (NMSQuest) 10.16 (5.42) 10.24 (5.24) 10.20 (5.31)
Hospital anxiety rating scale (HADSa) 5.49 (3.95) 6.16 (4.14) 5.85 (4.06)
Hospital depression rating scale (HADSd) 5.15 (3.68) 5.14 (3.73) 5.14 (3.70)
Beliefs about medication questionnaire (BMQ) 51.83 (9.48) 51.93 (8.09) 51.88 (8.74)
Number who need help with their medication (n) 19 27 46
PTA Parkinson’s tracker app, TAU treatment as usual
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symptom control or reduced QoL, younger age or longer disease
duration, and regime complexity or polypharmacy) and demo-
graphic (lack of spouse or partner, low income, employment
status, and gender) factors.24 We only excluded those with
signiﬁcant cognitive impairment as diagnosed by the clinical
team. Baseline HADS scores suggested that a majority of the
participants did not have depression or anxiety. There was an
indication that women were more adherent than men, but this
was not statistically signiﬁcant. The average age and duration of
PD was 61 years and 4 years respectively. Most participants took
all their medications on their own with 20.2% (n = 19) in the PTA
group and 25.2% (n = 27) in the TAU group needing help to take
their medications.
Composite QoL scores as measured on the PDQ-39 were low at
baseline, indicating that this was not a signiﬁcant contributor to
the outcome. Further investigation is recommended on the
impact of improved adherence on non-motor symptoms.25
However, this could be a chance ﬁnding or a placebo effect, as
we had not included a formal non-motor symptom assessment.
PD patients desire more emotional support from healthcare
professionals and want more active involvement in clinical
decision-making.11 Other studies have found that PD patients
who perceived higher involvement in their care were more
satisﬁed with the consultation and intended to be more compliant
with treatment.26 Those in the PTA group perceived the service as
more patient-centred as measured on the PCQ-PD (p = 0.01). This
could be linked to clinical teams inviting patients to use the app,
personalising the app set-up and jointly reviewing progress using
the data collected by patients at the 16-week follow-up.
User retention is a recognised challenge for all Smartphone
apps, with less than one in seven people opening apps beyond a
day after download.27 The higher level of user retention during
the SMART-PD trial can be linked to factors including the simplicity
and design of the app’s user interface and user experience; that
the app is perceived as given by participant’s clinical team and
thereby acting as an extension of their recommended care; and
the direct beneﬁt of understanding their health better as reported
by PTA users.
Table 2. Co-morbidities and symptoms for which medications were taken
Cardiovascular disease
Hypertension, cardiac arrhythmias (atrial ﬁbrillation), heart failure (congestive heart failure), coronary artery disease (angina, ischaemic heart disease),
peripheral vascular disease
Rheumatology and bone disease
Osteoporosis, osteoarthritis, gout, dermatomyositis
Psychological medicine
Depression, anxiety, panic attacks, psychosis (PD related), insomnia, sleep disturbances, parasomnia (REM sleep disorder), substance abuse / alcohol
dependence
Endocrine disorders
Hypothyroidism, hyperthyroidism, calcium deﬁciency, menopause
Neurological disorders
Stroke, spasticity, erectile dysfunction, PD related: pain, cramps, excess secretions
Gastrointestinal disease
Irritable bowel syndrome (IBS), Crohn’s disease, gastrointestinal reﬂux/acidity, constipation (PD related), hiatus hernia
Metabolic disorders Hypercholesterolaemia, diabetes
Respiratory disease
Asthma, sarcoidosis, inﬂammatory lung disease, sleep apnoea, allergy
Malignant disease Prostrate cancer and related urinary urgency
Haematological disease Anaemia, vitamin B12 deﬁciency
Skin disease Urticaria
Eye disorders Glaucoma
Supplements Anti-oxidants, cod liver oil, vitamins
Others Hypotension, infection, nausea
Table 3. Change in mean scores on the MMAS-8 between PTA and TAU groups at 16 weeks (intention-to-treat population)
Variable Statistics/Category PTA TAU All
Morisky medication adherence scale (MMAS-8) n 68 90 158
Mean (SD) 6.30 (1.52) 5.74 (1.53) 5.98 (1.55)
GLM analysis Difference and 95%CI 0.39 (0.04,0.74)
P-value 0.0304
Covariate adjusted GLM analysisa Difference and 95%CI 0.38 (0.03,0.73)
P-value 0.0331
PTA Parkinson’s tracker app, TAU treatment as usual, GLM generalised linear model
aAge, gender, number of co-morbidities, PD duration were used as covariates
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The trial included only those who already had smartphones or
tablet devices, thereby excluding those who did not own such a
device. Smartphone penetration in the UK is estimated at 66%,
ranging from 88% in those aged 25–34 to 49% in those aged
55–64 and 17% in those over 65.28 These later groups are the most
represented in the study group. The study app was available on
iOS (Apple operating system) and Android (Google operating
system). These were the major operating systems during the study
period (August 2014–June 2015) with 42.33% being iOS users and
47.95% being Android users. We estimate that users of other
operating systems (i.e. 9.72% of total smartphone and tablet
device users during the study period used Windows and Black-
berry)29 could not take part, further contributing to the reported
response rate. As the smartphone market penetration increases,
especially in those over 65, it would be anticipated that more
patients would be able to use the study app. It should be noted
that a mean age of 60 in the PTA group was not a barrier for
interaction with the PTA, allaying fears that technology-based
interventions are not appropriate for an older age group.
Our results also clearly highlight the difﬁculty of studying
adherence using a pragmatic design. Research into recruitment
rates for randomised controlled trials (RCTs)30 highlight the
challenges of both recruiting patients and of retentaining recruited
patients despite implementing various retention strategies along
with letters. Since we did not use any other methods of retention,
this could explain the study retention rate we found in the study—
there was a higher than expected loss to follow-up and survey
completion rates (64% in PTA arm and 83% in the TAU arm
completed as Per Protocol). We relied on the use of online
questionnaires that patients completed at home, rather than a
standard paper-based questionnaire completed at the clinic during
study visits, which likely led to the rate of drop-out. However,
questionnaires delivered and completed by the patient at home
have the beneﬁt of reduced recall bias and in-situ data collection. It
is possible that follow-up drop-outs preferentially affect those with
poor self-reported medication adherence, the difference in medica-
tions adherence between study arms were maintained in both
intention-to-treat and per-protocol analysis. The higher study drop-
out rate in the PTA group is likely due to the participants needing to
perform an additional trial task of using the PTA compared to the
TAU group. Additionally, the PTA may not have met all participants’
needs (for example: some of the self-monitoring measures chosen
by the trial team may not be applicable to some participants), which
could have contributed to the dropouts.
The MMAS-8 was developed to manage hypertension20 and the
MMAS-4 has been used in PD studies.31 A 2-point improvement on
the MMAS-8 scores was found to link to clinically signiﬁcant
improvement in hypertension.32 However, there are no similar
measures of the MMAS-8 in PD. Some studies investigating
adherence chose participants with lower adherence33 as criteria
for inclusion in a trial, which translates to an increased potential
for improvement. We did not exclude patients with high self-
reported adherence, indicating that PTA can help a range of
people with varying levels of adherence.
To study the impact of the PTA on health services use, we need
to assess the PTA over a longer duration. Although it seems
reasonable to conclude that improvement in adherence is
desirable, speciﬁcs around how much self-reported adherence is
clinically meaningful in PD will require additional studies looking
speciﬁcally at clinician and carer measures.
In summary, we conclude that the PTA could be an effective
and novel way of enhancing short-term self-reported medication
adherence and quality of clinical consultation by supporting self-
management in PD.
Table 4. Comparison of age at screening, gender, number of co-morbidities and duration of Parkinson’s disease between PTA and TAU groups
n, mean (SD) GLM analysis
Subgroup variable Category PTA TAU Difference and 95%CI p-value
Age at screening (year)
≤61 33,6.08 (1.49) 45,5.69 (1.53) 0.08 (−0.44,0.59) 0.7752
>61 35,6.51 (1.54) 45,5.79 (1.54) 0.70 (0.23,1.17) 0.0036
Gender
Male 43,6.33 (1.52) 52,5.86 (1.49) 0.29 (−0.17,0.75) 0.2108
Female 25,6.24 (1.56) 38,5.58 (1.58) 0.51 (−0.03,1.04) 0.0636
Number of comorbidities
≤1 43,6.13 (1.64) 59,5.94 (1.45) 0.21 (−0.18,0.60) 0.2892
>1 25,6.59 (1.26) 31,5.37 (1.63) 0.84 (0.15,1.54) 0.0167
Parkinson’s disease duration (year)
≤4 37,6.56 (1.30) 52,5.88 (1.55) 0.47 (−0.03,0.96) 0.0630
>4 31,5.98 (1.71) 38,5.56 (1.50) 0.33 (−0.17,0.83) 0.1917
GLM generalised linear model, PTA Parkinson’s tracker app, TAU treatment as usual
Fig. 2 Change in adherence categories: PTA and TAU
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METHODS
An open-label, multicentre RCT was conducted from August 2014 to June
2015. The objective was to compare the use of smartphone and internet-
enabled PTA with TAU for 16 weeks among patients with PD across 7
centres in England and Scotland (John van Geest Centre for Brain Repair,
Cambridge University Hospitals NHS Trust, Cambridge UK; King’s College
Hospital NHS Foundation Trust, London, UK; Newcastle upon Tyne
Hospitals NHS Foundation Trust, Newcastle, UK; NHS Forth Valley, Scotland,
UK; St. George’s Healthcare NHS Trust, London, UK; The Walton Centre NHS
Foundation Trust, Liverpool, UK ; University Hospitals Birmingham NHS
Foundation Trust, Birmingham, UK.) Ethics was obtained from the National
Research Ethics Service London–Westminster Research Ethics Committee
(13/LO/1783). Details of the trial are available in the trial protocol.34
Eligibility criteria were drawn up in a pragmatic manner to demonstrate
both the effectiveness and the ease of implementation of the PTA if used
in routine clinical practice.
Inclusion criteria included, (i) a diagnoses of probable, idiopathic PD, (ii)
on one or more Parkinson’s medications not altered within the previous
month and not expected to change during the trial period, and, (iii)
English-speaking and literate with access to a smartphone and/or tablet or
internet on a daily basis at home. Key exclusion criteria included
Table 7. PTA use frequency and volume of data input
App usage frequency during study period No. of days
Average number of days tracked during study period 48
Maximum number of days tracked 113
App data input volume during study period Number
Average no. of symptom scores entered in motif interface 629
Maximum no. of symptom scores entered 3608
Median no. of symptom scores entered 565
Table 8. PTA user retention after trial period (as of March 2016)
No. of participants
Tracking for >182 days (i.e. >6 months) 18
Tracking for >365 days (i.e. >12 months) 3
Days
Longest use recorded 510
Table 5. Difference in mean scores on secondary outcomes between PTA and TAU groups at 16 weeks (intention-to-treat population)
n, mean (SD) GLM analysis
Variable PTA TAU Difference and 95%CI p-value
QoL (PDQQoL-39) 68,155.47 (28.16) 89,150.75 (25.62) −0.22 (−3.95,3.52) 0.9102
Patient-Centred Questionnaire for Parkinson’s Disease (PCQ-PD) 68,2.03 (0.48) 89,1.85 (0.54) 0.15 (0.03,0.27) 0.0110
Non-Motor Symptoms Questionnaire (NMSQuest) 68,9.82 (5.68) 89,10.66 (4.89) −0.82 (−1.75,0.10) 0.0822
Hospital Anxiety Rating Scale (HADSa) 68,6.03 (4.15) 89,6.31 (4.21) 0.30 (−0.42,1.01) 0.4136
Hospital Depression Rating Scale (HADSd) 68,5.26 (3.73) 89,5.53 (3.90) 0.03 (−0.63,0.70) 0.9195
Beliefs about Medication Questionnaire (BMQ) 68,51.84 (8.85) 89,52.19 (7.97) −0.42 (−2.16,1.32) 0.6355
GLM generalised linear model, PTA Parkinson’s tracker app, TAU treatment as usual
Table 6. PTA user retention over trial period (August 2014–June 2015)
(n= 68)
Proportion of trial complete
25% 50% 75% 100%
Number of days used 28 56 84 112
Number of patients using app 56 56 53 49
Proportion of patients retained 82% 82% 78% 72%
Fig. 3 Screenshot of PTA self-tracking interface
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(i) suspected Parkinsonism due to causes other than idiopathic PD, (ii)
current or previous treatment for side effects of prolonged neuroleptic
treatment and, (iii) a diagnosis of dementia or signiﬁcant cognitive
impairment or major psychiatric illness associated with psychosis or a
major, serious comorbid illness (as recorded in patient case ﬁle).
Parkinson’s tracker app
The clinical team identiﬁed potentially eligible patients across the seven
trial sites from the clinic lists 6 weeks prior to upcoming outpatient (OP)
appointments. An information pack containing a patient invitation letter, a
participant information sheet and a consent form was sent to potential
participants 3–4 weeks prior to their next OP clinic appointment. At the OP
appointment, the clinician rechecked eligibility criteria and administered
the informed consent.
Following consent, patients were randomised to either the PTA or the
TAU group. They completed the baseline questionnaires at the clinic or
were asked to complete it at home within 1 week of their OP appointment
and were given the date for follow-up. Apart from consent forms, no
paper-based questionnaires or forms were used.
Patient questionnaires were administered online using a secure
research-grade questionnaire tool (Qualtrics) and other data was collected
using site speciﬁc OpenClinica electronic Research Form.
Those allocated to the PTA arm received instructions from their clinical
team to download the PTA to their Android or iPhone smartphones or
tablet devices (using the free ‘uMotif’ app from the Google Play Store or
Apple App Store) or to access it via a website portal within 1 day after they
have attended their OP appointment.
The app consisted of the following features:
1. A sliding petal interface to track ten self-monitoring measures,
chosen by the trial team, on a 5-point scale: including sleep, exercise,
mood, energy, movement, suppleness (Fig. 3). An accessibility mode
with a zoom function to magnify the screen was included.
2. A reminder system for patients to set up to allow the patient to
receive alerts to help track medication (Fig. 4)
3. An option to generate a report of data entered by the patient over
the trial period as an aid at their 16 week follow-up appointment
(Fig. 5)
4. Games to track physical responsiveness (ﬁnger-tapping task) (Fig. 6)
and cognition (number-size Stroop test)
5. Information about PD from Parkinson’s UK and the Cure Parkinson’s
Trust
Participants were asked to set up medication reminders and use the app
once a day or if not possible at least on alternate days over 16 weeks. They
also received a call from their clinician after 2 weeks to check if they, (i) had
completed the baseline study questionnaires, (ii) had downloaded the app
and, (iii) were having any difﬁculties with the PTA. At the 16-week visit
participants used the data they collected on their app during their
consultation. Technical support was available for patients via email
throughout the study if they experienced problems with the PTA.
Participants in the TAU group received a call from their clinicians after
2 weeks to check if they had completed the study questionnaires. At the
16 weeks appointment, they had their regular OP clinical assessments,
Fig. 4 Screenshot of PTA medication reminders Fig. 5 Screenshot of PTA report
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including symptom review followed by a medication review. Participants in
the TAU group were offered access and use of the PTA after their 16 weeks
of TAU
Participants in both groups received a reminder phone call from their
clinician 1 to 2 weeks prior to the follow-up appointment. Participants
completed the end of trial questionnaires within 1 week after their 16-
week follow-up appointment.
Participants in both arms had 2 contacts at the clinic. Visit 1 included
talking through the consent, randomisation and giving access to the app if
allocated to the intervention. This took between 30–45min Visit 2 at the
end of the study period included reviewing the data collected in the app
for the intervention and for control included inviting to the app and lasted
30min
Recruitment was originally planned as a rolling programme over the
course of 16 weeks until recruitment targets are achieved. However, we
extended the recruitment by another 6 months to help recruit the required
patient numbers.
Outcome measures
The primary outcome measure was self-reported adherence to treatment
as determined by Morisky Medication Adherence Scale (MMAS-8).35 This is
a self-report eight-item scale with response categories of ‘yes’ or ‘no’ for
each item and a 5-point Likert response for the last item. Higher responses
indicate better adherence. Secondary outcome measures included:
1. Parkinson’s Disease Questionnaire (PDQ-39):36 Measures eight
dimensions of QoL–mobility, activities of daily living, emotional
wellbeing, stigma, social support, cognition, communication and
bodily discomfort. Lower total scores reﬂect better QoL.
2. Patient-Centered Questionnaire for PD:37 (PCQ-PD) to measure
changes in quality of consultation. PCQ-PD is a self–completed
questionnaire addressing forty-four care aspects in six subscales
(information, multidisciplinary collaboration, accessibility, empathy,
patient involvement and emotional support) of patient-centered-
ness.
3. Non-Motor Symptom Questionnaire:38 A 30-item self-completed
questionnaire featuring responses as “yes,” or “no” to each item.
4. Hospital Anxiety and Depression Scale:39 A self-screening ques-
tionnaire for anxiety and depression. It consists of 14 questions with
seven each for anxiety and depression.
5. Beliefs about Medication Questionnaire:40 A self-administered
questionnaire and comprising of two subscales: An 11-item
questionnaire relating to prescribed medication and an 8-item
questionnaire relating to general views about taking medication.
Respondents rate each item on a ﬁve point Likert-type scale
depending on their degree of agreement (1 strongly disagree,
5 strongly agree). Higher scores indicate higher levels of concern or
strong beliefs towards the use of medication.
All measures were collected at baseline and at end of the trial period of
16 weeks.
Sample size
The sample size calculation was based on the primary endpoint. To detect
a 1-point improvement on the MMAS-8 with a standard deviation (SD) of
2.5 and 80% power at the 5% signiﬁcance level would require 200 subjects
(100 in each group, 1:1 allocation). To allow for 10% loss due to dropouts
and those lost to follow-up, we aimed to recruit 222 subjects (111 in each
group, 1:1 allocation).
Randomisation and masking
Eligible patients were allocated in a 1:1 ratio to the two arms of the study
according to a computer-generated random sequence stratiﬁed by centre
and using blocks of variable size. The allocation sequence was generated
by an independent statistician and was not available to any member of the
research team until databases were completed and locked. Copies of the
allocation sequence were not held at the recruiting centres. Once
randomised, clinicians who enroled participants informed them of their
assignment. Blinding to group allocation was not possible, as participants
knew whether or not they were receiving PTA. The trial statisticians were
blinded to the treatment code when developing the statistical analysis
plan and writing the statistical programmes, which were validated and
completed using dummy randomisation codes. The actual allocation code
was only provided to the trial statisticians after locking of the database and
ﬁnalisation of the statistical analysis plan.
Statistical methods
A Generalised Linear Model (GLM) was used for analysis of the primary
endpoint and had treatment as the ﬁxed effect and baseline measurement
of the primary endpoint as the covariate. The treatment difference together
with its 95% conﬁdence interval between PTA and TAU in the least square
mean of primary endpoint was derived from the GLM model. Model
assumptions about residuals in regression analysis were checked by
inspection of residuals vs. a ﬁtted values plot and no serious violation of
normality assumption was found. In addition, adjusted analysis and
subgroup analysis with pre-speciﬁed covariates (age, gender and number
of co-morbidities) were performed. For the secondary outcomes (QoL,
depression, anxiety, non-motor symptoms, and degrees of depression and
anxiety and quality of consultation), the analyses were performed in an
analogous fashion within the framework of GLM. Analyses of the primary and
secondary outcomes were carried out in adherence to the intention-to-treat
principle. In addition, supplemental per-protocol analyses were performed.
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